Comment on

• Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?

  Delongchamps NB, Lefèvre A, Bouazza N, Beuvon F, Legman P, Cornud F. Delongchamps NB, et al. J Urol. 2015 Apr;193(4):1198-204. doi: 10.1016/j.juro.2014.11.002. Epub 2014 Nov 11. J Urol. 2015. PMID: 25451824
• Impact of real-time elastography on magnetic resonance imaging/ultrasound fusion guided biopsy in patients with prior negative prostate biopsies.

  Brock M, Löppenberg B, Roghmann F, Pelzer A, Dickmann M, Becker W, Martin-Seidel P, Sommerer F, Schenk L, Palisaar RJ, Noldus J, von Bodman C. Brock M, et al. J Urol. 2015 Apr;193(4):1191-7. doi: 10.1016/j.juro.2014.10.106. Epub 2014 Nov 4. J Urol. 2015. PMID: 25451832
• The prostate health index selectively identifies clinically significant prostate cancer.

  Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. Loeb S, et al. J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15. J Urol. 2015. PMID: 25463993 Free PMC article.